Shawver Laura 4
4 · ARS Pharmaceuticals, Inc. · Filed Mar 7, 2025
Insider Transaction Report
Form 4
Shawver Laura
Director
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2025-03-06−49,600→ 74,064 totalExercise: $4.85Exp: 2032-01-31→ Common Stock (49,600 underlying) - Sale
Common Stock
2025-03-05$11.00/sh−400$4,400→ 210,346 total - Exercise/Conversion
Common Stock
2025-03-05$4.85/sh+400$1,940→ 210,746 total - Sale
Common Stock
2025-03-06$11.21/sh−49,600$556,046→ 210,346 total - Exercise/Conversion
Common Stock
2025-03-06$4.85/sh+49,600$240,560→ 259,946 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-03-05−400→ 123,664 totalExercise: $4.85Exp: 2032-01-31→ Common Stock (400 underlying)
Footnotes (3)
- [F1]The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
- [F2]The weighted average sale price for the transaction reported was $11.2106 and the range of prices were between $11.00 and $11.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]Immediately exercisable.